Exhibit 16.1
February 23, 2018
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549-7561
Dear Sirs/Madams:
We have read the statements made by Innovate Biopharmaceuticals, (formerly Monster Digital, Inc.) which we understand will be filed with the Securities and Exchange Commission, pursuant to Item 4.01 of Form 8-K, as part of the Form 8-K of Innovate Biopharmaceuticals, Inc. dated February 23, 2018. We agree with the statements concerning our Firm in such Form 8-K.
Very truly yours,
/s/ CohnReznick LLP
Roseland, New Jersey